275 related articles for article (PubMed ID: 36525230)
1. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer.
Conde-Moreno AJ; González-Del-Alba A; López-Campos F; López López C; Requejo OH; de Castro Carpeño J; Chicas-Sett R; de Paz Arias L; Montero-Luis Á; Pérez AR; Font EF; Arija JÁA
Clin Transl Oncol; 2023 Apr; 25(4):897-911. PubMed ID: 36525230
[TBL] [Abstract][Full Text] [Related]
2. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer.
Rodríguez Pérez A; Felip Font E; Chicas-Sett R; Montero-Luis Á; de Paz Arias L; González-Del-Alba A; López-Campos F; López López C; Hernando Requejo O; Conde-Moreno AJ; Arranz Arija JÁ; de Castro Carpeño J
Clin Transl Oncol; 2023 Apr; 25(4):882-896. PubMed ID: 36525231
[TBL] [Abstract][Full Text] [Related]
3. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.
Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ
Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390
[TBL] [Abstract][Full Text] [Related]
4. The management of oligometastatic disease in colorectal cancer: Present strategies and future perspectives.
Carconi C; Cerreti M; Roberto M; Arrivi G; D'Ambrosio G; De Felice F; Di Civita MA; Iafrate F; Lucatelli P; Magliocca FM; Picchetto A; Picone V; Catalano C; Cortesi E; Tombolini V; Mazzuca F; Tomao S
Crit Rev Oncol Hematol; 2023 Jun; 186():103990. PubMed ID: 37061075
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiation therapy for metastatic lung metastases.
Kimura T; Fujiwara T; Kameoka T; Adachi Y; Kariya S
Jpn J Radiol; 2022 Oct; 40(10):995-1005. PubMed ID: 36097233
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study.
Stefanovic M; Calvet G; Pérez-Montero H; Esteve A; Bujalance MV; Navarro-Martín A; Fernández MDA; González FF; Borras SM; Borbalas AL; Fernandez MN; Garau MM; Calduch AL; Edo FG
Clin Transl Oncol; 2023 Jan; 25(1):199-206. PubMed ID: 36068449
[TBL] [Abstract][Full Text] [Related]
7. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract][Full Text] [Related]
8. Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
Nevens D; Jongen A; Kindts I; Billiet C; Deseyne P; Joye I; Lievens Y; Guckenberger M
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):587-595. PubMed ID: 35738308
[TBL] [Abstract][Full Text] [Related]
9. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
[TBL] [Abstract][Full Text] [Related]
10. A Contemporary Update on the Role of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases in the Evolving Landscape of Oligometastatic Disease Management.
Robin TP; Raben D; Schefter TE
Semin Radiat Oncol; 2018 Oct; 28(4):288-294. PubMed ID: 30309639
[TBL] [Abstract][Full Text] [Related]
11. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
[TBL] [Abstract][Full Text] [Related]
12. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.
Lievens Y; Guckenberger M; Gomez D; Hoyer M; Iyengar P; Kindts I; Méndez Romero A; Nevens D; Palma D; Park C; Ricardi U; Scorsetti M; Yu J; Woodward WA
Radiother Oncol; 2020 Jul; 148():157-166. PubMed ID: 32388150
[TBL] [Abstract][Full Text] [Related]
13. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases.
Verma V; Yegya-Raman N; Sprave T; Han G; Kantarjian HM; Welsh JW; Chang JY; Lin SH
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):977-988. PubMed ID: 35675852
[TBL] [Abstract][Full Text] [Related]
15. Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
Kent CL; McDuff SGR; Salama JK
Ann Palliat Med; 2021 May; 10(5):5954-5968. PubMed ID: 32921069
[TBL] [Abstract][Full Text] [Related]
16. Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.
Moretto R; Rossini D; Zucchelli G; Lonardi S; Bergamo F; Santini D; Cupini S; Tomasello G; Caponnetto S; Zaniboni A; Antoniotti C; Pietrantonio F; Buonadonna A; Marmorino F; Bordonaro R; Fea E; Tamburini E; Boccaccino A; Grande R; Aprile G; Falcone A; Cremolini C
Eur J Cancer; 2020 Nov; 139():81-89. PubMed ID: 32979645
[TBL] [Abstract][Full Text] [Related]
17. Oligometastatic Disease and Local Therapies: A Medical Oncology Perspective.
Hafez N; Gettinger S
Cancer J; 2020; 26(2):144-148. PubMed ID: 32205539
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic radiotherapy in oligometastatic cancer.
Kennedy TAC; Corkum MT; Louie AV
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
[TBL] [Abstract][Full Text] [Related]
19. Oligometastasis in breast cancer-current status and treatment options from a radiation oncology perspective.
Piroth MD; Krug D; Feyer P; Baumann R; Combs S; Duma MN; Dunst J; Fastner G; Fietkau R; Guckenberger M; Haase W; Harms W; Hehr T; Sedlmayer F; Souchon R; Strnad V; Budach W
Strahlenther Onkol; 2022 Jul; 198(7):601-611. PubMed ID: 35527272
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
Phillips R; Shi WY; Deek M; Radwan N; Lim SJ; Antonarakis ES; Rowe SP; Ross AE; Gorin MA; Deville C; Greco SC; Wang H; Denmeade SR; Paller CJ; Dipasquale S; DeWeese TL; Song DY; Wang H; Carducci MA; Pienta KJ; Pomper MG; Dicker AP; Eisenberger MA; Alizadeh AA; Diehn M; Tran PT
JAMA Oncol; 2020 May; 6(5):650-659. PubMed ID: 32215577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
